CD^＋4 CD^＋25 调节性T细胞与急性髓细胞白血病关系的研究  

Relationship of CD^＋4 CD^＋25 regulatory T cells and acute myeloid leukemia

作　　者：陶盛能[1] 王会平[1] 沈元元[1] 卢娟[1] 赵一鸣[1] 翟志敏[1] 

机构地区：[1]安徽医科大学第二附属医院血液内科,合肥230601

出　　处：《白血病．淋巴瘤》2009年第11期654-656,共3页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金（30771954）

摘　　要：目的 探讨CD^＋4 CD^＋25 调节性T细胞（CD^＋4 CD^＋25 Treg细胞）在急性髓细胞白血病（AML）患者化疗前后外周血中的表达水平及其临床意义。方法 采用流式细胞术检测AML初发组（A组）、缓解3年内组（B组）、缓解3年以上组（C组）及正常对照组外周血中CD^＋4 CD^＋25 CDlow127 T细胞所占比例。结果 A组和B组外周血中CD^＋4 CD^＋25 Treg细胞比例均高于对照组（P＜0.05）；C组外周血CD^＋4 CD^＋25 Treg细胞比例与对照组相比差异无统计学意义（P＞0.05）；B组外周血中CD^＋4 CD^＋25 Treg细胞比例高于C组（P＜0.05）；A组外周血中CD^＋4 CD^＋25 Treg细胞比例明显高于B、C两组（P＜0.05）。结论 CD^＋4 CD^＋25 Treg细胞与AML发生有关，尤其与3年内容易复发密切相关。Objective To investigate the proportion of CD^＋4 CD^＋25 Tregs in the peripheral blood of the patients suffering from acute myeloid leukemia （AML） with or without chemotherapy and clinical significance.Methods The flow cytometry was used to evaluate the proportion of CD^＋4 CD^＋25 CDlow127 T cells in the peripheral blood of the patients with primary AML group（group A）, AML who achieved complete remission over 3 years（group C） or less than 3 years（group B） and the healthy donors. Results The percentages of CD^＋4 CD^＋25 Tregs of group A and B was significantly higher than that of control group（P 〈0.05）; but not significantly defferent among the group C and control group（P 〉0.05）. The percentages of CD^＋4 CD^＋25 Tregs of group A was significantly higher than that of group B and C. Conclusion These results suggested that CD^＋4 CD^＋25 Tregs played an important role in acute myeloid leukemia.

关 键 词：白血病 CD^+4 CD^+25 调节性T细胞 CD127 

分 类 号：R733.7[医药卫生—肿瘤]